Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: September Update

Performance overview
Value at beginning of month: $97,956.98
Value at end of month: $115,325.33
Month over month change: +17.73%
Total CAGR: 20.94%

Related indices, monthly change
NASDAQ: +3.68%
IVV (iShares Core S&P 500): +2.74%
IBB (iShares NASDAQ Biotechnology Index): +7.25%
MXI (iShares Global Materials): +2.35%
VEGI (iShares MSCI Global Agriculture Producers): +4.61%
ICLN (iShares Clean Energy): -0.72%

Individual performances


The index had its best month ever, reaching record highs. Its gains came from Genscript and Calyxt, who make up around 30% of the index and both gained over 50% in September. Intrexon, which accounts for another 25% of the index was also modestly up.

Changes made to index

None, you can view the index here.

Allocation as of September 30, 2017


Calvin Schmidt Synthetic Biology Index: October Update

Calvin Schmidt Synthetic Biology Index: August Update